Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.79)
# 580
Out of 5,182 analysts
222
Total ratings
54.96%
Success rate
6.84%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Reiterates: Overweight | $800 | $744.44 | +7.46% | 23 | Apr 23, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $45 → $54 | $57.78 | -6.54% | 17 | Apr 8, 2026 | |
| AMGN Amgen | Reiterates: Neutral | $350 | $340.18 | +2.89% | 20 | Apr 8, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $240 | $197.38 | +21.59% | 19 | Apr 8, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $135 → $155 | $127.75 | +21.33% | 17 | Feb 11, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $985 → $1,205 | $868.27 | +38.78% | 15 | Feb 5, 2026 | |
| PFE Pfizer | Reiterates: Neutral | $27 | $26.79 | +0.78% | 17 | Feb 4, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $116 → $120 | $110.23 | +8.86% | 12 | Feb 4, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $104.04 | +7.65% | 2 | Oct 31, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $426.01 | +13.85% | 4 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $59.72 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $128.04 | +28.87% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $40.81 | -50.99% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $180.67 | -0.37% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $14.12 | +324.93% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.63 | +376.19% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.53 | +488.24% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $61.60 | +54.22% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $7.38 | +171.00% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $115.07 | -36.56% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $2.35 | +410.64% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.35 | +330.42% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $123.91 | +206.67% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $95.72 | -14.33% | 5 | Jan 16, 2019 |
Regeneron Pharmaceuticals
Apr 23, 2026
Reiterates: Overweight
Price Target: $800
Current: $744.44
Upside: +7.46%
Bristol-Myers Squibb Company
Apr 8, 2026
Maintains: Neutral
Price Target: $45 → $54
Current: $57.78
Upside: -6.54%
Amgen
Apr 8, 2026
Reiterates: Neutral
Price Target: $350
Current: $340.18
Upside: +2.89%
AbbVie
Apr 8, 2026
Maintains: Overweight
Price Target: $250 → $240
Current: $197.38
Upside: +21.59%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $135 → $155
Current: $127.75
Upside: +21.33%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $985 → $1,205
Current: $868.27
Upside: +38.78%
Pfizer
Feb 4, 2026
Reiterates: Neutral
Price Target: $27
Current: $26.79
Upside: +0.78%
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $116 → $120
Current: $110.23
Upside: +8.86%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $104.04
Upside: +7.65%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $426.01
Upside: +13.85%
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $59.72
Upside: -
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $128.04
Upside: +28.87%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $40.81
Upside: -50.99%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $180.67
Upside: -0.37%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $14.12
Upside: +324.93%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.63
Upside: +376.19%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.53
Upside: +488.24%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $61.60
Upside: +54.22%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $7.38
Upside: +171.00%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $115.07
Upside: -36.56%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $2.35
Upside: +410.64%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.35
Upside: +330.42%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $123.91
Upside: +206.67%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $95.72
Upside: -14.33%